Get the Stockscreener App
6.30
0.00%
0.00
Pre-market:
6.12
-0.18
-2.86%
Trevi Therapeutics Inc stock is traded at $6.30, with a volume of 1.76M.
It is up +0.00% in the last 24 hours and up +55.56% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$6.30
Open:
$6.3
24h Volume:
1.76M
Relative Volume:
0.65
Market Cap:
$563.00M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-21.72
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
+43.51%
1M Performance:
+55.56%
6M Performance:
+90.91%
1Y Performance:
+117.99%
1-Day Range:
$5.98
$6.49
1-Week Range:
$4.24
$7.39
52-Week Range:
$2.30
$7.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
6.30 | 563.00M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock - Investing.com India
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock By Investing.com - Investing.com Australia
Biotech Alert: Searches spiking for these stocks today - TipRanks
Investors Buy High Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $20.00 at Oppenheimer - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High After Analyst Upgrade - Defense World
Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Wednesday - Defense World
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 - Nasdaq
Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer - TipRanks
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Upgraded to Strong-Buy at Raymond James - Defense World
Needham & Company LLC Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Given New $12.50 Price Target at HC Wainwright - Defense World
Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Kilgore News Herald
Trevi Therapeutics stock soars to 52-week high of $6.58 By Investing.com - Investing.com Australia
Trevi Therapeutics reports positive Phase 2a trial results - Investing.com
Trevi Therapeutics Just Got a 212% Price Target Bump – Here’s Why - Wall Street Pit
Cough in Idiopathic Pulmonary Fibrosis Pipeline 2024: MOA, ROA, - openPR
Leerink raises Trevi Therapeutics stock target to $11 - Investing.com
Leerink raises Trevi Therapeutics stock target to $11 By Investing.com - Investing.com Canada
HC Wainwright Adjusts Trevi Therapeutics Price Target to $12.50 From $7.50, Maintains Buy Rating - Marketscreener.com
Trevi Therapeutics stock soars to 52-week high of $6.58 - Investing.com
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Raymond James Upgrades Trevi Therapeutics (TRVI) - Nasdaq
Trevi Therapeutics price target raised to $11 from $7 at Leerink - TipRanks
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps - Yahoo Finance
Trevi Therapeutics price target raised to $25 from $8 at Needham - TipRanks
Trevi’s mid-stage chronic cough data meet ‘home run’ scenario, stock soars - Endpoints News
Trevi hits 4-year high as chronic cough therapy succeeds in study - TradingView
Trevi Therapeutics meets main goal in chronic coughing treatment trial, stock surges - MSN
Needham raises Trevi Therapeutics stock target to $25 - Investing.com
Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James - TipRanks
Trevi Therapeutics stock soars on positive trial results - Investing.com
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket - Benzinga
Trevi jumps as chronic cough therapy succeeds mid-stage trial - TradingView
Trevi Therapeutics Announces Positive Topline Results From Its Phase 2a RIVER Trial Of Haduvio For Treatment Of Patients With RCC - Marketscreener.com
Trevi Therapeutics RIVER trial meets primary endpoint - TipRanks
Clinical Trial Success: Haduvio Achieves 57% Cough Reduction in Phase 2a RCC Study - StockTitan
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough - The Malaysian Reserve
Can Trevi's Phase 2a Chronic Cough Drug Change Treatment Landscape? Data Coming - StockTitan
Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from D. Boral Capital - Defense World
Head-To-Head Comparison: Trevi Therapeutics (NASDAQ:TRVI) vs. CSL (OTCMKTS:CSLLY) - Defense World
Can Trevi's Chronic Cough Treatment Impress Investors? Leadership Team Set for March Conference Circuit - StockTitan
Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPF - Clinical Trials Arena
Trevi Therapeutics Completes Enrollment For Phase 2B Coral Trial -February 25, 2025 at 09:36 am EST - Marketscreener.com
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - Marketscreener.com
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough – Company AnnouncementFT.com - Financial Times
Trevi Therapeutics (NASDAQ:TRVI) Receives “Buy” Rating from D. Boral Capital - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Average PT from Brokerages - Defense World
Oppenheimer Adjusts Trevi Therapeutics Price Target to $12 From $9, Maintains Outperform Rating - Marketscreener.com
Trevi Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Trevi Therapeutics Inc Stock (TRVI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Simon Farrell | Chief Commercial Officer |
Mar 10 '25 |
Sale |
6.75 |
81,313 |
548,878 |
76,900 |
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):